PBI10 Cost Effectiveness Analysis for the Treatment of Psoriasis: The Use of Adalimumab Biosimilars
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.08.088
https://www.valueinhealthjournal.com/article/S1098-3015(20)32344-5/fulltext
Section Title :
Section Order :
10059
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32344-5&doi=10.1016/j.jval.2020.08.088